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Background: Convincing evidence on Virtual Reality (VR) exposure for phobic anxiety
disorders has been reported, however, the benchmark and golden standard for
phobia treatment is in vivo exposure. For direct treatment comparisons, the control of
confounding variables is essential. Therefore, the comparison of VR and in vivo exposure
in studies applying an equivalent amount of exposure in both treatments is necessary.
Methods: We conducted a systematic search of reports published until June
2019. Inclusion criteria covered the diagnosis of Specific Phobia, Social Phobia,
or Agoraphobia, and a randomized-controlled design with an equivalent amount of
exposure in VR and in vivo. We qualitatively reviewed participants’ characteristics,
materials, and the treatment procedures of all included studies. For quantitative
synthesis, we calculated Hedges’ g effect sizes for the treatment effects of VR exposure,
in vivo exposure, and the comparison of VR to in vivo exposure in all studies and
separately for studies on each diagnosis.
Results: Nine studies (n = 371) were included, four on Specific Phobia, three on
Social Phobia, and two on Agoraphobia. VR and in vivo exposure both showed large,
significant effect sizes. The comparison of VR to in vivo exposure revealed a small,
but non-significant effect size favoring in vivo (g = −0.20). Specifically, effect sizes
for Specific Phobia (g = −0.15) and Agoraphobia (g = −0.01) were non-significant,
only for Social Phobia we found a significant effect size favoring in vivo (g = −0.50).
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Except for Agoraphobia, effect sizes varied across studies from favoring VR to favoring
in vivo exposure.
Conclusions: We found no evidence that VR exposure is significantly less efficacious
than in vivo exposure in Specific Phobia and Agoraphobia. The wide range of study
specific effect sizes, especially in Social Phobia, indicates a high potential of VR, but
also points to the need for a deeper investigation and empirical examination of relevant
working mechanisms. In Social Phobia, a combination of VR exposure with cognitive
interventions and the realization of virtual social interactions targeting central fears might
be advantageous. Considering the advantages of VR exposure, its dissemination should
be emphasized. Improvements in technology and procedures might even yield superior
effects in the future.
Keywords: anxiety disorder, agoraphobia, social anxiety, specific phobia, exposure therapy, virtual reality,
meta-analysis, systematic review
INTRODUCTION
Rationale
Phobic Anxiety Disorders
Phobic anxiety disorders (ICD-10 F40) are listed as a
subcategory of anxiety disorders in the ICD-10 (World
Health Organization, 1992). They are characterized by anxiety in
circumscribed situations, which currently pose little or no actual
danger, and by an avoidance of those situations or an endurance
with dread (World Health Organization, 1992). There are three
subtypes of phobic anxiety disorders in the ICD-10 (World
Health Organization, 1992): Agoraphobia (F40.0), Social Phobia
(F40.1), and Specific Phobia (F40.2). Patients with Specific
Phobia fear specific situations or objects such as animals, heights,
thunder, darkness or closed spaces. Social Phobia patients report
fear of scrutiny by other people, which leads to an avoidance
of social situations. Agoraphobia is characterized by a fear of
situations in which fleeing from the situation or help is not
easily accessible, such as crowds in public spaces, leaving home,
entering shops, or traveling alone in a train, bus or plane. It
can be coded with (F40.01) or without (F40.00) Panic Disorder.
Other anxiety disorders (ICD-10 F41) include Panic Disorder
(F41.0), or generalized anxiety disorders (GAD) (F41.1) (World
Health Organization, 1992). Both anxiety disorders are related
to internal stimuli, like bodily sensations in panic disorder and
worries in GAD.
Twelve-month prevalence rates for phobic anxiety disorders
have been reported to range from 0.3 to 1.6% for Agoraphobia,
1.2 to 6.8% for Social Phobia, and 3.5 to 8.7% for Specific Phobia
(Bijl et al., 1998; Alonso et al., 2004; Kessler et al., 2005; Stein
et al., 2017;Wardenaar et al., 2017; Stagnaro et al., 2018). Lifetime
prevalence rates have been reported to range from 0.9 to 3.4%
for Agoraphobia, 2.4 to 7.8% for Social Phobia, and 7.7 to 10.1%
for Specific Phobia (Bijl et al., 1998; Alonso et al., 2004; Kessler
et al., 2005; Stein et al., 2017; Wardenaar et al., 2017). Prevalence
rates for the subtypes of Specific Phobia have been reported to
range from 3.3 to 5.7% for animal phobia, 4.9 to 11.6% for natural
environment phobia (with 3.1 to 5.9% for height phobia), 5.2 to
8.4% for situational phobia (with 2.5 to 2.9% for flying phobia),
and 3.2 to 4.5% for blood, injury and injection phobia (LeBeau
et al., 2010).
With evidence from prospective studies, anxiety disorders
must be seen as chronic disorders, starting in childhood,
adolescence or early adulthood with a peak in middle age and a
decrease in older age (Bandelow andMichaelis, 2015). According
to the Global Burden of Disease Study 2015, anxiety disorders
are ranked as the ninth largest contributor to global disability,
leading to a global total of 24.6 million years lived with disability
(YLD) in 2015 (Vos et al., 2016). For Specific Phobia, 18.7% of
people with a 12-month Specific Phobia diagnosis reported severe
role impairment in at least one out of four domains consisting
of home, work, relationships and social life, and a mean number
of 12.2 days out of role in the past year was assessed due to the
disorder (Wardenaar et al., 2017). For Social Phobia, 37.6% of
people with a 12-month diagnosis stated a severe role impairment
in at least one domain, and a mean number of 24.7 days out of
the role per 1 year was reported (Stein et al., 2017). For Panic
Disorder with Agoraphobia, 84.7% of people with a 12-month
diagnosis described severe role impairment, and for Agoraphobia
without a history of Panic Disorder, but including panic attacks,
39.0% reported severe impairment (Kessler et al., 2006).
Exposure Therapy
The first-line treatment for anxiety disorders consists of exposure
therapy (Chambless et al., 1998; Wolitzky-Taylor et al., 2008;
Bandelow et al., 2014; Barlow et al., 2015; Steinman et al., 2015).
During exposure therapy, patients confront themselves over a
long period of time, repetitively, with a feared external or internal
stimulus until distress has decreased significantly. They are also
advised not to use cognitive or behavioral avoidance strategies.
During exposure therapy in phobic anxiety disorders, patients
particularly confront themselves with external stimuli such as
height in fear of heights, crowds in Agoraphobia, or giving a
speech in front of an audience in Social Phobia. This can be
conducted in their imagination (exposure in sensu) or in real live
(exposure in vivo). Exposure therapy in other anxiety disorders
differs slightly from the procedure in phobic anxiety disorders.
In panic disorder, interoceptive exposure to internal stimuli in
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the form of bodily sensations like heartbeat or dizziness are
mainly applied (see for e.g., Forsyth et al., 2008; Gerlach and
Neudeck, 2012). In Agoraphobia, interoceptive exposure is used
in addition to in vivo exposure to external stimuli. In GAD
treatment, patients confront themselves with internal or external
aspects of their anxiety (Overholser and Nasser, 2000; Hoyer and
Beesdo-Baum, 2012). Through imaginal exposure, GAD patients
are exposed to central worries (e.g., concerning physical injury
or impaired health), and through in vivo exposure, patients
expose themselves to daily-live situations that elicit worries while
not using safety behaviors such as telephone calls. In PTSD, a
stress-related disorder, imaginal exposure to traumatic memories
is performed and can be combined with in vivo exposure to
daily-life actions (e.g., a patient traumatized by a car accident
drives a car) (Riggs et al., 2007; Friedman, 2015). Besides
anxiety disorders and PTSD, exposure therapy is also conducted
in other disorders like obessive compulsive disorder (Lewin
et al., 2014), eating disorders (see for e.g., Griffen et al., 2018;
Waller and Raykos, 2019), or substance addiction (Marlatt, 1990;
Drummond et al., 1995), respectively, with a modified procedure.
With phobic anxiety disorders as the focus of this systematic
review and meta-analysis, there is robust empirical evidence
for the efficacy of exposure therapy, even as the sole treatment
method. According to numerous studies, in vivo exposure
shows high effect sizes in the treatment of Agoraphobia
(Ruhmland and Margraf, 2001), Social Phobia (Mayo-Wilson
et al., 2014) and Specific Phobia (Wolitzky-Taylor et al.,
2008). The most approved mechanisms underlying exposure
treatment are habituation, extinction, correction of negative
beliefs, and emotional processing (Foa and Kozak, 1986; Clark,
1999). Above that, inhibitory learning was recognized to be
central to extinction learning (Craske et al., 2008). The authors
propose that fear toleration, the development of competing
non-threatening associations, and the enhancement of the
accessibility and retrievability of those associations from different
context and time, are more important for corrective learning
than fear levels and fear reduction during exposure (Craske
et al., 2008). Exposure is often performed in combination
with further cognitive behavioral therapy (CBT) interventions
such as psychoeducation, cognitive interventions, or relapse
prevention strategies. While for Specific Phobia such additional
interventions are minimal in many approaches, e.g., in the
very effective One-Session Treatments (Davis et al., 2012),
exposure in Social Phobia is typically integrated in further
cognitive behavioral interventions and is particularly framed as
experimental tasks, focusing on the verification and correction of
dysfunctional beliefs in social situations (Clark, 2001).
Despite its convincing theoretical and empirical foundation,
there seem to be barriers in the dissemination of exposure
therapy in routine care. Neudeck and Einsle (2012) mention
structural barriers (e.g., time, insurance, or logistics) and barriers
up to the therapist (e.g., negative attitudes toward exposure
therapy or insufficient familiarity with the method). Both impede
the (accurate) application of exposure techniques in clinical
practice. These barriers cause a problem for patients, preventing
them from receiving highly efficacious treatment.
Virtual Reality Exposure Therapy
The use of Virtual Reality (VR) technology represents an option
with the potential to overcome such barriers. VR exposure
therapy (VRET), also called exposure therapy in virtuo, is
based on the very similar rationale of in vivo exposure therapy,
however, in VR exposure, phobic stimuli are presented to the
patient in VR. VR is a computer-generated presentation, which
provides input to the user’s sensory system and interacts with
the user (also see Diemer et al., 2015). Visual VR stimuli are
presented via VR glasses (HMD: head mounted display) or via
projection-based systems like CAVE-systems (cave automatic
virtual environment), which is a room with up to six projection
sides. Auditory input is applied via loudspeakers or earphones,
and tactile, haptic or olfactory stimulation is possible but rarely
provided. The aim is to replace sensory input from the real
world and to create a presence of the user in the virtual world.
To interact with the user in real time, the VR system collects
information about the users’ position and (head) movements
via sensors and input devices like a head tracking system or
a joystick.
By bringing virtual phobic stimuli into the therapist’s office,
VR exposure has many structural advantages. It is less time
consuming in its application (e.g,. because driving to a high tower
in heights phobia treatment is not necessary any more), cost-
effective (e.g., in comparison to cost-intensive in vivo treatments
for fear of flying), and requires less organization (e.g., regarding
the acquisition of living spiders in spider phobia treatment, or of
an audience for Social Phobia treatment). Furthermore, there are
fewer difficulties concerning safety and insurance arrangements.
Above that, the VR technique might enhance usage of
exposure treatment through a higher acceptance by patients,
and thereby ease an efficacious procedure of psychotherapy. For
in vivo exposure in Specific Phobia, high treatment responses
but low treatment acceptance and high dropout rates have been
reported in the past (Choy et al., 2007). In a direct comparison,
García-Palacios et al. (2007) found evidence that patients with
Specific Phobia prefer VR exposure to in vivo exposure and
are significantly more willing to participate in VR treatment,
mostly because they are too afraid of confronting the real
feared stimuli. Quero et al. (2014) examined patients with Panic
Disorder and Agoraphobia concerning their opinion toward VR
and traditional interoceptive exposure before, directly after, and
3 months after treatment. Both treatments were well-accepted at
all three time points, although VR exposure was considered a
little, but not significantly, less aversive. Before treatment, the VR
exposure rationale was expected to be significantly more logical
and useful in other problems. Interestingly, higher expectations
before treatment predicted a better clinical improvement at the
post-test and follow-up. After 3 months, participants in the
traditional interoceptive exposure group reported a significantly
higher satisfaction. Nevertheless, clinical improvements did not
show significant differences between the two conditions at the
post-test and follow-up. Concerning dropout from an ongoing
exposure treatment, a meta-analysis of randomized-controlled
trials (RCTs) conducted by Benbow and Anderson (2018) found
no significant difference in the likelihood of discontinuation
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between VR and in vivo exposure, although the attrition rate
for VR exposure was found to be slightly below estimates
reported for in vivo exposure and CBT for anxiety disorders.
Thus, offering VR exposure might, in particular, lead to a higher
number of patients agreeing to exposure therapy. During and
after exposure therapy, on the other hand, an application in
VR might not have relevant advantages with regards to dropout
rates—at least if patients were randomly assigned to either VR or
in vivo therapy—or with regards to the patients’ opinion toward
the treatment.
Besides the patients’ acceptance, VR provides the advantage
that phobic objects and situations can be easily adapted according
to therapeutic considerations. For example, the therapist can
entirely control type, intensity, duration and repetition of the
exposed object or situation, and can implement specific stimuli
(e.g., turbulences in the exposure of flight phobia) (Diemer et al.,
2015). Furthermore, contextual shifts are less time consuming
and costly in VR in comparison to in vivo exposure (Botella et al.,
2017), what might be relevant as usingmultiple contexts in spider
phobia already showed an improvement in the generalizability of
exposure therapy (Shiban et al., 2015). Altogether, VR provides
a high level of control and flexibility with the possibilities to
even surpass reality (Botella et al., 2017). One example is the
use of virtual spiders, which can be constructed to be much
bigger than living spiders (see for e.g., Shiban et al., 2015).
These possibilities might even facilitate an enhancement of the
efficacy of VR in comparison to in vivo exposure therapy,
although empirical evidence from studies explicitly exhausting
the technical possibilities of VR exposure are still rare.
Finally, the German Practice Guideline for anxiety disorders
already recommends VR exposure on the basis of expert
consensus for Specific Phobia if in vivo exposure is not available
or possible (Bandelow et al., 2014). Moreover, the guideline
preliminarily lists VR therapy as an effective treatment option for
Agoraphobia/Panic Disorder.
Efficacy of Virtual Reality Exposure Therapy for
Phobic Anxiety Disorders
To empirically prove the efficacy of VR exposure therapy in
anxiety disorders, numerous original studies and meta-analyses
have been published throughout the last decade. While some
of the meta-analyses highlight a broad perspective on the use
of VR in cognitive behavioral therapy, including other VR-
based interventions than exposure (Fodor et al., 2018), or show
effect sizes for symptom improvements through VR exposure
under the inclusion of primary studies that applied no control
group (Parson and Rizzo, 2008), most meta-analyses focus on
comparisons of VR exposure to inactive and active control
conditions. According to the Cochrane Handbook for Systematic
Reviews of Interventions, inactive control groups consist of for
example a placebo, no treatment, standard care, or a waitlist
control, while active control groups consist of a different kind
of therapy (Higgins and Green, 2011). Results from previous
meta-analyses on the efficacy of VR exposure therapy for anxiety
disorders showed that VR exposure therapy yields large effects
with regards to the reduction of anxiety symptoms (Parson and
Rizzo, 2008) and greatly outperforms inactive control conditions
(Powers and Emmelkamp, 2008; McCann et al., 2014; Fodor
et al., 2018; Carl et al., 2019). Compared to active treatment
conditions, results were more indifferent. Two meta-analyses
showed no significant difference in the efficacy of VR exposure
for anxiety disorders in comparison to classical evidence-based
treatments like CBT, imaginal exposure and in vivo exposure
(Opris¸ et al., 2012), or when specifically compared to in vivo
exposure therapy (Carl et al., 2019). In contrast, Fodor et al.
(2018) found that non-VR interventions like CBT, imaginal
exposure, and in vivo exposure were slightly more effective than
VR exposure in anxiety disorders. Powers and Emmelkamp
(2008) instead reported a small effect size favoring VR exposure
over in vivo exposure for anxiety disorders. As further results,
Opris¸ et al. (2012) showed that gains from VR exposure therapy
could be transferred to real life situations, and that VR exposure
showed a good stability of its outcomes over time, similar to
that of classical evidence-based treatments, yet, there is evidence
that deterioration rates of VR therapy for anxiety disorders
did not differ significantly from other therapeutic approaches
and were less frequent in comparison to waitlist control groups
(Fernández-Álvarez et al., 2018).
In addition to addressing different anxiety disorders, some
meta-analyses focused on the efficacy of VR exposure in specific
kinds of Phobias. Morina et al. (2015) conducted a meta-
analysis on fear of heights and fear of spiders in particular.
The examination of behavior changes in real life situations
and stability over time showed that VR exposure performed
significantly better than waitlist did as an inactive control
condition, and that there were no significant differences between
VR exposure therapy and in vivo exposure therapy as an active
control condition. Cardos¸ et al. (2017) conducted a meta-analysis
on flight phobia in particular. They reported an advantage of VR
exposure therapy when compared to classical evidence-based-
interventions at the post-test and follow up, and when compared
particularly to imaginal or in vivo exposure at follow up but not
at post-test. In a meta-analysis on Social Phobia in particular,
Chesham et al. (2018) showed no relevant difference between VR
and imaginal or in vivo exposure.
Notably, there were different primary studies included in the
reported meta-analyses. Regarding the meta-analyses addressing
different anxiety disorders, Parson and Rizzo (2008) examined
the effects of VR exposure therapy for Phobias and PTSD in
studies without a control group, with waitlist, bibliotherapy,
relaxation, or attention as inactive control groups, or with
in vivo exposure as an active control group. The meta-analysis
by Fodor et al. (2018) provides a broader perspective on the
use of VR in cognitive behavioral therapy and in this regard
examined RCTs on VR-enhanced exposure and also on VR-
enhanced CBT interventions without exposure. However, in
two particular subgroup analyses, VR-enhanced exposure only
was compared to inactive control conditions including waitlist,
placebo, treatment-as-usual, and relaxation, and to active control
conditions including CBT, imaginal exposure, and in vivo
exposure. Carl et al. (2019) synthesized trials on anxiety disorders
and PTSD with random or matched allocation and compared
VR exposure conditions, in which VR was not combined
with another intervention, medication, or placebo to mixed
control conditions like wailtlist, information, attention control,
treatment as usual, relaxation, or present-centered therapy, and
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to in vivo exposure as an active control condition. McCann
et al. (2014) synthesized RCTs on different anxiety disorders and
compared VR exposure to waitlist or active placebo as inactive
control groups, and to active control groups which in this study
constisted of interventions like treatment as usual, cognitive
therapy, present centerd therapy, computer-aided exposure, CBT,
imaginal exposure, or in vivo exposure. Powers and Emmelkamp
(2008) examined RCTs on anxiety disorders and PTSD and
compared VR conditions that do not combine VR with other
interventions or medication, to inactive control groups like
waitlist, attention control, bibliotherapy, or relaxation, and to
in vivo exposure as active control group. Opris¸ et al. (2012)
examined RCTs on anxiety disorders comparing VR conditions
to waitlist as inactive control group, and to classical evidence-
based treatments like CBT, imaginal exposure and in vivo
exposure as active control groups in a clinical population.
Regarding the reported meta-analyses addressing particular
Phobias, Morina et al. (2015) synthesized studies on Specific
Phobia and compared the efficacy on behavioral outcome
measures in VR based exposure interventions with inactive
control conditions like waitlist or attention placebo, and with
active control conditions like CBT, imaginal exposure or in vivo
exposure. Cardos¸ et al. (2017) included RCTs on flight phobia
and compared VR exposure treatments with or without other
interventions, to waitlist or attention control as inactive control
groups, and to classical evidence-based interventions like CBT,
bibliotherapy, cognitive therapy, relaxation, CBT with standard
exposure (in vivo), relaxation techniques with imaginal exposure,
and computer aided exposure as active controls, and particularly
to exposure-based interventions including imaginal and in vivo
exposure as active control groups. Chesham et al. (2018) included
studies on Social Phobia with random, quasi-random or matched
assignment, and compared VR exposure conditions to waitlist as
inactive control group, and to in vivo or imaginal exposure as
active control conditions.
Overall, only two studies (Powers and Emmelkamp, 2008;
Carl et al., 2019) conducted a quantitative meta-analysis on
the efficacy of VR exposure therapy in comparison to in vivo
exposure therapy as the gold standard treatment for phobic
anxiety disorders. No previous meta-analysis considered the
amount of exposure applied in VR and in vivo conditions.
This reduces the internal validity of previous results, because
differences in effect sizes between VR and in vivo exposure
therapy cannot be clearly attributed to the application mode of
exposure treatment but could be due to differences in the load of
exposure treatment.
Objectives
As the first systematic review and meta-analysis, we aim at
comparing the efficacy of VR and in vivo exposure therapy
for phobic anxiety disorders, based on randomized controlled
trials including an equivalent amount of exposure in VR and
in vivo. We chose to focus on phobias, as they are a highly
comparable group of anxiety disorders with a similar procedure
of exposure treatment. In these disorders, in vivo exposure as an
individual treatment component is considered the gold standard.
Furthermore, there are concrete external phobic stimuli that are
usually presented during in vivo exposure, and these stimuli can
be directly transferred to VR.
In our quantitative meta-analysis, we evaluate pre to post
effect sizes for VR exposure therapy, in vivo exposure therapy,
and for the comparison of VR and in vivo exposure therapy.
Furthermore, we report the individual effect sizes of all included
studies and provide a systematic review of the participants’
characteristics, the materials, and the treatment procedures used.
On this basis, we aim at discussing potential mechanisms of more
or less efficacious VR exposure therapy.
Other than the recent meta-analysis by Carl et al. (2019),
which provides a broad overview of the topic, our focus is the
direct comparison of an equivalent amount of exposure in VR
and in vivo. In this regard, we apply stricter inclusion criteria
than Carl et al. (2019) to control for potential confounding
variables. We exclude not only studies with a different amount
of exposure in the VR and in vivo condition, but also studies with
imaginal exposure but no in vivo exposure as the control group,
with exposure treatment applied only to selected participants,
with VR presentation without using immersive systems (e.g.,
HMD) and head tracking, and with dependent samples. Since
Carl et al. (2019) do not provide a qualitative review of their
included studies, we furthermore fill this gap. We therefore
offer detailed descriptions and assessments of the individual
studies’ characteristics and of differences in their individual effect
sizes. We summarize the patients’ characteristics as well as the
treatment materials and procedures, including information on
the exposure strategy, the type of HMDs and their technical
features, the virtual and in vivo environments, and additional
interventions along with the exposure that were applied in the
VR and in vivo exposure condition. As VR exposure is a quickly
expanding field, high quality meta-analyses and high resolutions
in research is needed to contribute to theory building, the
development of future research questions, and the improvement
of VR exposure procedures.
Research Question
We examine whether there is a relevant difference in the efficacy
of VR exposure therapy in comparison to in vivo exposure
therapy as the gold standard treatment for phobic anxiety
disorders, when synthesizing RCTs with an equivalent amount of
exposure in the VR and in vivo condition. Furthermore, we aim
at a qualitative examination of the participants’ characteristics,
materials, and treatment procedures of all the included studies.
METHODS
Protocol
We used the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) checklist and protocol provided
by the PRISMA Group (Moher et al., 2009).
Eligibility Criteria
Only original studies published until June 2019 were included.
The language inclusion criterion was (1) a report written in
English or German. The population inclusion criterion was (2)
an ICD or DSM diagnosis for Agoraphobia, Specific Phobia,
or Social Phobia. The intervention inclusion criteria were (3) a
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treatment for Agoraphobia, Specific Phobia, or Social Phobia,
(4) exposure therapy in virtual reality using immersive systems
(e.g., HMD) and head tracking (no augmented reality or 3D
computer animation in front of a PC screen) in the experimental
group, (5) exposure therapy in vivo in the control group, and
(6) no combination of the VR or in vivo exposure therapy
with a specific psychopharmacological treatment. The outcomes
inclusion criterion was that (7) studies examined the reduction
of phobic anxiety as the primary outcome. To ensure an high
internal and external validity, the inclusion criteria for study
design were (8) a minimum number of 10 participants per group,
(9) a randomized assignment of the participants to one of both
exposure conditions, (10) an equivalent amount of exposure in
both conditions and equivalency concerning additionally applied
interventions alongside exposure treatment, (11) a pre and post
measurement of phobic anxiety (12) with a symptom specific,
standardized questionnaire or interview, and (13) sufficient
statistical values (means and standard deviations in outcome
parameters for each group).
Information Sources
A literature search in PubMed, PsychInfo andWeb of Science was
conducted in October and November 2017 and was updated in
November 2018 and in June 2019. We also asked experts in the
field of VR therapy to provide possible eligible studies.
Search
We searched for the keywords “virtual” and “phobia” in the
PubMed, PsychInfo and Web of Science databases. Moreover,
we conducted a search on the term “social anxiety.” We did
not set a time limit for the period in which the studies were
conducted. Depending on the different databases’ search template
structure, we used slightly different search strategies. In PubMed
the connector ‘AND’ was used to search for “Virtual AND
Phobia” as well as “Virtual AND anxiety AND social” in titles
and abstracts. In PsycInfo we searched for “virtual” in title and
“phobia” in abstracts, as well as for “virtual” in title and “anxiety”
and “social” in abstracts. In Web of Science we searched for
“virtual” in title and “phobia” in the topic, as well as for “virtual”
in title and “anxiety” and “social” in the topic.
Study Selection
A PRISMA flow diagram (Moher et al., 2009) illustrates the
number of studies screened and excluded during the screening
process (see Figure 1). Therefore, the numbers from the first
search in November 2017 and the updated search in November
2018 and June 2019 were summed up. During screening process
of all records identified through database searching (n = 1,126)
and other source (n = 3), obvious duplicates (n = 143) were
removed first. The titles and abstracts of the remaining reports
(n = 986) were then screened against the eligibility criteria. If
a title or abstract provided the information that at least one
eligibility criterion was not fulfilled, the record was excluded
(n= 944). All remaining records with no evidence for a violation
in eligibility criteria within the abstract were passed on for full-
text screening (n = 42). During this process, all 13 eligibility
criteria were assessed, and reports not fitting every eligibility
criterion were excluded (n = 33). We contacted two authors
to check on dependent samples in different records to avoid
including data twice. One author provided the information that
there was no overlap in the samples of two flight phobia studies
(Rothbaum et al., 2000, 2006). The other author informed us that
one eligible record (Robillard et al., 2010) includes preliminary
data from a larger study (Bouchard et al., 2016), so we excluded
the preliminary data from our meta-analysis.
There were three researchers involved in the screening
process. One researcher screened the titles and abstracts of all
studies, and then screened the full-text of the remaining studies
providing suggestions for the selection of eligible reports. A
second researcher additionally screened the abstracts and full-
text and selected eligible reports. Disagreements concerning the
inclusion of studies after the full-text screening of two researchers
were discussed with the third researcher. We performed the
exclusion process based on the information provided in the
published articles and to the best of our knowledge.
Data Collection Process
Data were extracted from each report independently by two
researchers. Means and standard deviations for the participants’
age and the distribution of sexes was missing in one report,
but we could not reach the respective author. One author was
contacted concerning missing information on the type of HMD
and the author provided the respective information. Technical
data on the image resolution and the field of view of HMDs
were collected from the reports, and if not available HMD data
sheets from internal databases and from the producers’ websites
were used. Because not all reports provided statistical data on
both, the intent-to-treat and the completer sample, we contacted
the respective authors to ask for additional data. As we could
not receive both data sets for every included study, we used the
intent-to-treat data if available, otherwise we used data from the
completer sample. Disagreements between the two researchers
concerning the collected data were discussed with the third
author until a consensus was reached.
Data Items
The following data were extracted: (1) number of participants in
total and in the VR and in vivo group, (2) age of the participants as
means, standard deviations and range, (3) distribution between
the sexes of the participants, (4) medication of the participants,
(5) treated disorder (Agoraphobia, Social Phobia, or Specific
Phobia), (6) number of total treatment sessions in the VR and
in vivo condition (exposure sessions plus additional sessions
applying other interventions), (7) amount of exposure in the
VR and in vivo condition, assessed in form of (7a) the number
of exposure sessions and (7b) the duration of exposure sessions
in minutes, (8) exposure strategy, (9) type of HMD with (9a)
resolution and (9b) field of view, (10) information on movement
mode and further stimulation of senses alongside the sense of
sight in VR, (11) description of the VR exposure environment,
(12) description of the in vivo exposure environment, (13)
therapeutic interventions used for pre- and post-processing and
to accompany exposure, (14) sample on which the calculation
of means and standard deviations was carried out on (intent-
to-treat vs. completer sample), (15) type of standardized
measurement for symptom specific anxiety, and (16) means and
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FIGURE 1 | PRISMA flow diagram (Moher et al., 2009) reporting the number of screened studies and the number of studies excluded during the screening process.
standard deviations of the pre- and post-symptom measurement
for the VR and in vivo group. If more than one symptom
measurement was applied, the measurement that assessed the
anxiety symptoms of the treated phobia the most specifically
was collected.
Risk of Bias in Individual Studies
Risk of bias in the individual studies was assessed using a tool
for bias detection in randomized trials from the Cochrane
Collaboration (Higgins et al., 2011). To assess the risk of
selection bias, performance bias, detection bias, attrition
bias, and reporting bias, we checked the criteria (1) random
sequence generation, (2) allocation concealment, (3) blinding of
participants and researchers, (4) blinding of outcome assessment,
(5) incomplete outcome data, and (6) selective reporting. The
risk of bias in each domain was rated as either low, unclear,
or high following the explanations and examples provided by
Higgins et al. (2011). We again performed this process based on
the information provided in the published articles and to the best
of our knowledge.
Synthesis of Results
Qualitative Review
As qualitative synthesis of all included studies, we conducted
a qualitative review. A qualitative review provides a structured
presentation and assessment of central characteristics of the
included studies. For this purpose, we examined and summarized
the participants’ characteristics, diagnostic measures, study
methodology, and treatment materials and procedures to provide
an overview and a basis for discussions on effect sizes
and future research perspectives. In the examination of the
treatment materials and procedures, we particularly considered
information on the exposure strategy, visual VR devices (type
of HMDs including technical data on resolution and field of
view), movement mode in VR, devices for further stimulation
of senses alongside the sense of sight in VR, VR and in vivo
exposure environments, and additional interventions alongside
the exposure applied in the VR and in vivo condition (see
collected data items in section Data Items).
Quantitative Meta-Analysis
To provide a statistical summary of the results on the efficacy
of VR and in vivo exposure therapy from the included studies
on phobic anxiety disorders, we performed a quantitative meta-
analysis. In this regard, we calculated pre- to post-effect sizes for
VR exposure, in vivo exposure, and the comparison of VR to
in vivo exposure for the individual studies and then synthesized
them for all included studies. In addition, we separately
calculated synthesized effect sizes of all studies on Specific
Phobia, Social Phobia and Agoraphobia. We used Microsoft
Word Excel 2016 as the software tool for the statistical analysis.
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Effect sizes for the individual studies
VR exposure therapy and in vivo exposure therapy. As a first
step, we calculated the pre- to post-effect sizes for (1) the VR
exposure treatment and (2) the in vivo exposure treatment of the
individual studies included in the meta-analysis. We therefore
computed the standardized mean difference between pre- and
post-measurement separately for the VR group and in vivo group
of each study using Cohen’s d for studies that use pre-post-
scores according to Borenstein et al. (2009). Because correlations
between the outcome measures were not available, the value
was set to zero, constituting a conservative calculation (Lenhard
and Lenhard, 2014). As an indicator corrected for small sample
bias, we computed the Hedges’ g (Hedges and Olkin, 1985).
The Hedges’ g coefficients were calculated by the multiplication
of Cohen’s d and a correction factor according to Borenstein
et al. (2009). In addition, variance, standard error and 95%
confidence interval for Hedges’ g were calculated. The Hedges’
g may be interpreted as small (0.2), medium (0.5), and large (0.8)
(Ellis, 2010).
Comparison of VR and in vivo exposure therapy. As a second
step, we calculated the pre- to post-effect sizes for (3) the
comparison of VR to in vivo exposure therapy for the individual
studies included in the meta-analysis. For each study, we
calculated the standardized mean difference by subtracting the
pre to post change in the in vivo group from the pre to post
change in the VR group, and then divided the result by the
pooled pre-test standard deviation (Morris, 2008). The standard
deviations were pooled across pretest scores of both conditions
as recommended by Morris (2008) as the best choice for pretest-
posttest-control group designs. Hedges’ g again was calculated
for the standardized mean difference using a correction factor
(Morris, 2008; Borenstein et al., 2009). The variance, standard
error and confidence interval for g were also calculated. The
variance of g was computed as the multiplication of the squared
correction factor and an approximation of the variance of the
uncorrected standardized mean difference, using an equation for
independent samples following Borenstein et al. (2009). In this
calculation, a positive Hedges’ g effect size reflects superiority of
the VR exposure treatment, while negative coefficients indicate
superiority of the in vivo exposure treatment.
Synthesis of effect sizes for all studies on phobic
anxiety disorders
To synthesize the effect sizes for VR exposure, in vivo exposure,
and the comparison of VR to in vivo exposure therapy from all
included studies on phobic anxiety disorders, we estimated total
mean effect sizes in a random-effect model following Borenstein
et al. (2009). A random-effect model accounts for the variation
across the studies and assumes that the true effects are normally
distributed (Borenstein et al., 2009). It therefore considers the
within-study variance and the variance between-studies.
Three random-effect models were calculated to synthesize the
individual effect sizes for (1) VR exposure, (2) in vivo exposure,
and (3) the comparison of VR and in vivo exposure from all
included studies. During the calculation of each model according
to Borenstein et al. (2009), an estimate for the between-studies
variance was computed first, using the method of moments.
Second, each study was weighted by the inverse of its variance
plus the estimated between-studies variance. Third, we estimated
the mean effect size. For this purpose, we calculated the weighted
mean of the Hedges’ g effect sizes of all studies, as the sum of
the weighted effect sizes of the individual studies, divided by the
sum of the weights. We also computed the variance, standard
error, confidence interval, Z-value and two-tailed p-value for the
estimated mean effect size.
Synthesis of effect sizes for studies on Specific Phobia, Social
Phobia, and Agoraphobia
In addition, we calculated synthesized effect sizes for VR
exposure, in vivo exposure, and for the comparison of VR to
in vivo exposure therapy separately for studies on Specific Phobia,
Social Phobia, and Agoraphobia. Because the estimate of the
between-studies variance, which is necessary to calculate the
random-effect model, has a poor precision if the number of
studies is very small (Borenstein et al., 2009), we calculated a
fixed-effect model as an option for a small number of studies
suggested by Borenstein et al. (2009). A fixed-effect model is
already reasonable for a synthesis up from two studies, because
a synthesis of two or more studies offers a more precise estimate
of the true effect compared to one study alone (Borenstein
et al., 2009). A fixed-effect model does not allow inferences on
a wider population but provides a descriptive analysis about the
included studies (Borenstein et al., 2009). It assumes that the
true effect size is the same in all studies included in the meta-
analysis (Borenstein et al., 2009). Although the fixed-effect model
actually demands functionally identical studies (Borenstein et al.,
2009), which is basically implausible in studies performed by
different researchers, it does however seem applicable for the
synthesis of studies on one kind of phobic anxiety disorder in this
meta-analysis, particularly because the inclusion criteria created a
relatively high homogeneity concerning the participants and the
procedure used across the studies.
The fixed-effect models were computed according to
Borenstein et al. (2009). Altogether, we calculated nine fixed-
effect models synthesizing the pre to post effect sizes for (1)
VR exposure therapy, (2) in vivo exposure therapy, and (3) the
comparison of VR to in vivo exposure therapy separately, for
all included studies on (1) Specific Phobia, (2) Social Phobia,
and (3) Agoraphobia. During the calculation of each fixed-effect
model, the effect size of each individual study was weighted by
the inverse of its own variance. The weighted mean was then
calculated as the sum of the weighted effect sizes, divided by
the sum of the weights. In addition, we computed the variance,
standard error, 95% confidence interval, Z-value and two-tailed
p-value for the summary effect using equations according to
Borenstein et al. (2009).
Risk of Bias Across Studies
To assess the risk of bias across the included studies, a funnel plot
with the standard errors for Hedges’ g on the axis of ordinates
and Hedges’ g on the axis of abscissae was conducted. We
therefore used Hedges’ g for the comparison of the VR and
in vivo condition, as the main result of our analysis. A skewed
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or asymmetrical funnel in a visual examination can indicate a
publication bias, as (smaller) studies that do not show statistically
significant effects remain unpublished (Easterbrook et al., 1991;
Egger et al., 1997).
RESULTS
Study Selection
The PRISMA flow-chart diagram (Figure 1) shows the number
of screened studies, excluded studies, and studies finally included
in the meta-analysis. During full-text assessment, 33 studies
were excluded because they did not fulfill the eligibility criteria
for the following reasons: presentation of 3-D-stimuli on a PC
screen instead of VR presentation using immersive systems (e.g.,
HMD) and head tracking (Klinger et al., 2005), comparison of
two different VR exposure groups but no comparison to an
in vivo exposure control group (Fraser et al., 2001), imaginal/in
sensu exposure but no in vivo exposure as the control group
(Wiederhold et al., 2001, 2002; Wallach et al., 2009; Rus-Calafell
et al., 2013; Triscari et al., 2015), interoceptive exposure but
no in vivo exposure as the control group (Quero et al., 2014),
interoceptive and imaginal exposure but no in vivo exposure as
the control group (Vincelli et al., 2003), computer-aided exposure
as the control group (Tortella-Feliu et al., 2011), in vivo exposure
only for patients with comorbid conditions in the control group
(Krijn et al., 2007), relaxation training as the control group
(Mühlberger et al., 2001), cognitive treatment as the control
group (Mühlberger et al., 2003; Wallach et al., 2011), evaluation
of VR exposure treatment effects on a graduation flight
conducted accompanied or alone but no comparison between
VR exposure and in vivo exposure as control group (Mühlberger
et al., 2006), no control group (Baños et al., 2002; Anderson
et al., 2003, 2005; Wald, 2004; Grillon et al., 2006; Piercey
et al., 2012; Felnhofer et al., 2014), combination of exposure
with paroxetine (Pitti et al., 2015), <10 participants per group
(Botella et al., 2000), no equivalent amount of exposure in the VR
and in vivo condition (Pelissolo et al., 2012), report of a study
protocol without results (Miloff et al., 2016), and no equivalency
concerning additional interventions applied alongside exposure
in the VR and in vivo condition (Miloff et al., 2019). In the
latter reports by Miloff et al. (2016, 2019), VR exposure was
conceptualized as a fully automated VR serious game constructed
to work independently from the presence of a human therapist.
In contrast, in vivo exposure was conducted as a single session
exposure approach according to Öst and was guided by a human
therapist. Therefore, the VR condition was confounded with an
automated exposure approach. As the in vivo exposure condition
furthermore consisted of additional interventions conducted by
the human therapist, that were not applied in the VR condition,
like reflection on catastrophic beliefs, exploration of what occurs
at each treatment stage, exploration of violations of expectancy
and monitoring and discussion of safety behaviors, the study
did not fulfill our inclusion criteria concerning equivalence
in the additional interventions applied alongside exposure in
the VR and in vivo condition and was thus excluded from
the analysis. The following studies were also excluded for the
exceptional reasons of a combination of VR exposure with in vivo
exposure (Choi et al., 2005), and as pilot trials, follow-up studies,
or studies that examined a new research question based on
the data of another screened study (Rothbaum et al., 2002;
Robillard et al., 2010; Safir et al., 2012; Anderson et al., 2016;
Kampmann et al., 2019).
Study Characteristics
Nine studies fulfilled all eligibility criteria and were included in
our meta-analysis (see Tables 1, 2 for study characteristics). The
final sample consisted of two studies on Agoraphobia (Botella
et al., 2007; Meyerbroeker et al., 2013), three on Social Phobia
(Anderson et al., 2013; Bouchard et al., 2016; Kampmann et al.,
2016), and four on Specific Phobia (Rothbaum et al., 2000, 2006;
Emmelkamp et al., 2002; Michaliszyn et al., 2010). As different
sub-types of Specific Phobia, two studies target fear of flying
(Rothbaum et al., 2000, 2006), one study targets fear of heights
(Emmelkamp et al., 2002), and one study targets fear of spiders
(Michaliszyn et al., 2010).
As presented in Table 1, the nine studies were published
between 2000 and 2016 and included data from 371 participants
overall, with a mean sample size of 41.22 patients (SD = 14.39).
All studies included participants with the ICD or DSM diagnosis
of a phobic anxiety disorder. In the two studies on flight phobia as
a Specific Phobia, also patients with an Agoraphobia with flying
as the main feared stimulus were included (Rothbaum et al.,
2000, 2006). In one study on Agoraphobia (Botella et al., 2007),
17.1% of all participants including a waitlist condition were
diagnosed with Panic Disorder without Agoraphobia. The study
on spider phobia as a Specific Phobia included four participants
with only a partial diagnosis of Specific Phobia who however
scored within the phobic range for the questionnaire measures
and behavioral avoidance task (Michaliszyn et al., 2010). The age
of the included participants ranged from 18 to 72 - referring to
those studies providing information on this sample characteristic
(see Table 1). In all studies except one (Emmelkamp et al., 2002),
more women than men were included, though one study did
not give information on the distribution of sexes (see Table 1).
Information on the percentage of medicated participants was
only available in three studies (Botella et al., 2007; Michaliszyn
et al., 2010; Bouchard et al., 2016) and showed a wide range
of medication rates from zero to 66.6%. The number of total
treatment sessions applied to each participant ranged from four
(Emmelkamp et al., 2002) to 14 (Bouchard et al., 2016), with a
mean total treatment session number of 8.78 (SD = 2.64). The
number of total treatment sessions includes exposure sessions as
well as additional sessions, for example with interventions like
psychoeducation or relapse prevention (see Table 2). As required
by the eligibility criteria of this meta-analysis (see section
Eligibility Criteria), the amount of exposure was equal in the VR
and in the in vivo exposure condition of all included studies.
The amount of exposure was typically assessed by the number of
exposure sessions, and the duration of one exposure session was
also considered. In all studies, the number of exposure sessions
performed in the VR and the in vivo group ranged from three
sessions (Emmelkamp et al., 2002) to eight sessions (Bouchard
et al., 2016) with a mean number of exposure sessions of 5.44 (SD
= 1.59). The duration of one exposure session ranged from 20 to
90min with amean duration of 54.29min (SD = 22.81) – though
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TABLE 1 | Participants’ and treatment characteristics in RCTs included in the meta-analysis.
Participants Treatment
References Age in years Sex (m/f) Medicated Total
sessions
Exposure sessions (VR
and in vivo condition)
N ICD or DSM
diagnosis
M (SD) range n or % n or % N n min./
session
Rothbaum
et al., 2000
30 Specific Phobia (fear of
flying)a
40.55 (10.64)e 24–69 29%/71%e N/A 8 4 N/A
Emmelkamp
et al., 2002
33 Specific Phobia (fear of
heights)
43.97 (9.34) N/A 18/15 N/A 4 3 60
Rothbaum
et al., 2006
58 Specific Phobia (fear of
flying)b
VRET: 38.62 (9.16)
IVET: 44.45 (12.16)
N/A 12/46 N/A 8 4 N/A
Michaliszyn
et al., 2010
32 Specific Phobia (spider
phobia)c
29.1 (7.99) 18–51 1/31 0 8 6 90
Anderson
et al., 2013
69 Social Phobia 39.03 (11.26)f 19–69 38.1%/
61.9%f
N/Ai 8 VRET: 4
IVET: 6k
VRET: 30
IVET: 20
Kampmann
et al., 2016
40 Social Phobia VRET:
39.65 (11.77)
IVET: 37.5 (11.27)g
18–
65g
VRET: 35%/65%
IVET:
25%/75%g
N/A 10 7 60
Bouchard
et al., 2016
39 Social Phobia VRET: 36.2 (14.9)
IVET: 36.7 (11.1)
N/A 7/32 VRET: 2
IVET: 3
14 8 20–30
Botella et al.,
2007
24 Agoraphobiad 34.7 (12.31)h 18–72 29.7%/70.3%h 66.6%h 9 6 60
Meyerbroeker
et al., 2013
46 Agoraphobia N/A 18–65 N/A N/Aj 10 6 60
The left side of this table presents the number of patients included in the individual studies, their ICD or DSM diagnosis, their age, the distribution of the sexes, and the number of
medicated patients. Age is reported as means and standard deviations either for the whole sample or separately for the both treatment groups VR exposure therapy (VRET) and in vivo
exposure therapy (IVET). The range of age is stated for the whole sample. The distribution of sexes is presented as absolute numbers or as percentages of male and female participants
and is reported either for the whole sample or separately for both treatment conditions. If information on medication was available, the absolute number or the percentage of medicated
participants was reported either for the whole sample or separately for both treatment conditions. The right side of the table gives an overview of the treatment sessions applied to
participants in the VR exposure and in the in vivo exposure condition. The total number of treatment sessions adds up the number of exposure sessions and the number of additional
sessions for pre-and post-processing and to accompany exposure. The number of exposure sessions and the duration of one single exposure session in minutes is reported, too. A
description of the concrete exposure procedures and interventions performed during additional sessions is summarized in Table 2. Studies are sorted by the type of phobia and date of
publication. N (total participants) = 371. N/A: information was not available.
aPatients diagnosed with Agoraphobia with flying as main feared stimulus, n = 3.
bPatients diagnosed with Agoraphobia (with or without Panic Disorder) with flying as main feared stimulus, n = 10.
cPatients with partial diagnosis of Specific Phobia but scoring within the phobic range on questionnaire measures and BAT, n = 4.
dParticipants with diagnosis of Panic Disorder without Agoraphobia in whole sample including waitlist, % = 17.1.
eValues for the whole sample including third condition (waitlist), N = 45.
fPercentages for whole sample including waitlist condition, N = 97.
gParticipants included in VR and in vivo group by re-randomization from waitlist are not included in values for mean age and sex distribution, but in age range.
hValues for whole sample including third condition (waitlist).
i Inclusion criteria consist of a stable medication for 3 months.
jTranquilizers excluded, stable dose of antidepressants required.
kDifferent number and duration of exposure sessions but with the same total duration of 120min in the VR exposure condition (four times 30min) and in the in vivo exposure condition
(six times 20min).
two studies did not give information on this treatment procedure
characteristic (see Table 1).
As presented in Table 2, the exposure strategy for both the VR
and in vivo group was described as gradual in all studies except
one. This study mentioned a special feature of their exposure
strategy, where the focus was to develop new, non-threatening
and adaptive interpretations, and that habituation was not
required (Bouchard et al., 2016). All studies applied a therapist
guided exposure approach in the VR and in vivo condition.
They all used HMD devices for visual stimuli presentation in
the VR exposure condition. Image resolution and field of view of
HMDs differed over the individual devices. The image resolution
determines how clean the picture quality is, while the field of view
(FoV) refers to the view or the surroundings that a human eye
can see without eye movements (Jerdan et al., 2018). One study
additionally used a CAVE system for visual stimuli presentation
but did not find significant differences in contrast to an HMD
presentation (Kampmann et al., 2016). For tactile and haptic
stimulation, two studies on flight phobia mentioned the use of
a specific seating construction in the VR condition (Rothbaum
et al., 2000, 2006), and one study on fear of heights used a railing
to hold on to (Emmelkamp et al., 2002). Some studies provided
information on the movement mode in VR andmentioned either
the use of a mouse (Botella et al., 2007; Michaliszyn et al.,
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TABLE 2 | Treatment materials and procedures in the VR and in vivo exposure conditions.
Exposure Treatment
References Exposure strategy
(VR and in vivo
condition)
Type of HMD with
image resolution
and field of view
Movement mode in
VR and devices for
tactile and haptic
stimulation
VR environments In vivo environments Additional interventions (VR and
in vivo condition)
Rothbaum et al.,
2000
Gradual; encouraging
comments by
therapist
VR6: 640 × 480/60◦ Thunderseata Window seat inside the passenger
compartment of a commercial
airplane with empty seats; takeoffs
and landings; flying in calm and
stormy weather
Airport: ticketing, trains, parked
planes, waiting area; sitting on
stationary plane (+ imaginal exposure
of take-offs, cruising, landing, etc. on
stationary planec)
Treatment planning and explaining the
rationale to the patients, anxiety
management techniques (breathing
retraining, cognitive restructuring,
thought stopping, in case of panic
attacks: hyperventilation exposure)
Emmelkamp
et al., 2002
Gradual; habituation
rationale; verbal
guidance and
encouragement by
therapist
Cybermind Visette
Pro: 640 × 480/71.5◦
Walk around freely on 1
m2; railing to hold on
Mall with four floors with escalators
and balustrades, fire escape (height:
∼50 feet), roof garden at top of
building (height: ∼65 feet)
Real locations corresponding to VR
environments
Intake session
Rothbaum et al.,
2006
Gradual VFX3D: 640 ×
480/35◦
Seat with seatbelt and
bass speaker
underneath
Window seat inside the passenger
compartment of a commercial
airplane; start of engines,
announcements of pilot and
attendants, taking the plane to the
runway, take-off, flying in bad and
good weather, landing
Airport: ticketing, trains, waiting area;
coordination center tower: viewing
planes, speaking with knowledgeable
airport personnel; sitting on stationary
plane (+ imaginal exposure of
take-offs, cruising, landing, etc. on
stationary planec)
Treatment planning, anxiety
management techniques (breathing
retraining, cognitive restructuring,
thought stopping, interoceptive
exposure)
Michaliszyn
et al., 2010
Gradual I-glasses PC/SVGA
A502085® (i-O
display systems): 800
× 600/26◦
Handheld wireless
gyration mouse
Three levels of animated spiders of
different shapes and sizes; top item:
large black-widow spider
Two types of spiders; top-item:
manipulate them in the hand
Psychoeducation, cognitive
restructuring, relapse prevention
Anderson et al.,
2013
Gradual; habituation
rational
VFX headset: 640 ×
480/35◦
N/A Virtual conference room (about five
audience members), virtual classroom
(35 audience members), virtual
auditorium (100 audience members);
different audience reactions
(interested, bored, supportive, hostile,
distracted, etc.); audience members
posing standardized or individualized
questions
Group therapy with up to five
participants, videotaped speech in
front of the other group members,
individualized positive feedback from
other group members
Psychoeducation, realistic goal
setting for social situations through
techniques like cognitive preparation,
challenging of cost and probability
biases, relapse prevention, homework
(daily mirror task, daily record of
social situations,identification of
cognitive bias)
Kampmann
et al., 2016
Gradual; until anxiety
decreased;
communication with
therapist in next room
via intercom
nVisor SX: 1,280 ×
1,024/60◦
N/A Giving a talk in front of an audience
followed by questions, talking to a
stranger, buying and returning
clothes, attending a job interview,
being interviewed by journalists,
dining in a restaurant with a friend,
having a blind date; semi-structured
dialogues with different
dialogue-styles and content (friendly
vs. unfriendly; personal relevance),
different number, gender and
gestures of avatars
Participants’ individual social
situations which were translated to
exposure exercises (e.g., in
supermarkets, subway stations,
cafés, etc.); or exposure in personal
environment of the participants with
contact to therapist via the telephone
before and after the exposure
Therapy rationale and anxiety
hierarchy, relapse prevention,
evaluation of the therapy
(Continued)
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TABLE 2 | Continued
Exposure Treatment
References Exposure strategy
(VR and in vivo
condition)
Type of HMD with
image resolution
and field of view
Movement mode in
VR and devices for
tactile and haptic
stimulation
VR environments In vivo environments Additional interventions (VR and
in vivo condition)
Bouchard et al.,
2016
Focus of the
exposure: develop
new, nonthreatening
and adaptive
interpretations;
habituation not
required; active
modeling from the
therapist in early
sessions
eMagin z800: 800 ×
600/40◦
Wireless computer
mouse
Speaking in front of audience in a
meeting room, having a job interview,
introducing oneself and having a talk
with supposed relatives in an
apartment, acting under the scrutiny
of strangers on a coffee shop patio,
facing criticism or insistence (meeting
unfriendly neighbors, refusing to buy
goods from a persistent seller at a
store); preformatted answers
triggered by the therapists
Role-playing and guided exposure
inside or outside the therapist’s office
(e. g. asking for the time in a coffee
shop, asking strangers on a date,
giving an awkward impromptu
speech to an audience of staff
members, making improper requests
in boutiques and stores); audience
constituted by laboratory members
Developing a personal case
conceptualization model, symptoms
and avoidance/safety behavior,
cognitive restructuring, relapse
prevention
Botella et al.,
2007
Gradual V6: 640 × 480/60◦ Mouse Training room, house, subway, bus,
shopping mall, tunnel; simulation of
bodily sensations (palpitations and
breathing difficulties with three levels
of intensity from mild to accelerated,
visual effects like tunnel vision, blurred
vision, double vision); different
modulations: number of people
present, length of the trips, difficulties
like problem with the credit card at
the shopping mall or the elevator
suddenly stopped between two floors
etc.
in vivo exposure Psychoeducation, cognitive
restructuring and breathing training,
interoceptive exposure, recording of
panic symptoms, relapse prevention
Meyerbroeker
et al., 2013
Gradual manipulation
of crowd density
in situations
nVisor SX: 1,280 ×
1,024/60◦ (or CAVE
with projection on
three walls and floorb)
N/A Supermarket, subway, Italian
restaurant with bar annex, town
center, large open square,
marketplace with market stalls, public
building with large open spaces and
different floors with café on the
ground floor; crowd density could be
manipulated
Supermarket, shopping malls,
marketplaces, streets and public
transportation (e.g., subway)
Psychoeducation, cognitive
restructuring, interoceptive exposure,
discussion of safety behaviors,
relapse prevention
This table provides detailed information on the exposure treatment materials and procedures and on additional interventions applied in participants of the included studies. It mentions the general exposure strategy that was similar in VR
and in vivo. Moreover, it gives information on the type of HMD used for visual stimuli presentation, including data on image resolution and field of view (FoV). The image resolution is reported by the number of pixels arranged horizontally
and vertically; the field of view is reported as diagonal FoV in degrees. If available, information on the movement mode in VR and on additional devices for tactile stimulation is provided. The table furthermore provides descriptions of the
VR and in vivo exposure environments and mentions psychological interventions that were applied in addition to pure exposure treatment in the VR as well as for the in vivo exposure condition. Studies are sorted by the type of phobia
and date of publication. N/A: no information available.
aSeat with woofer under it to create noise and vibrations.
b In this study, a CAVE system was used in addition to HMD as an alternative mode for VR presentation. No significant effects of HMD vs. CAVE were found on outcome-measures.
c Imaginal exposure was conducted during in vivo exposure on a stationary plane.
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2010; Bouchard et al., 2016), or that the participants could walk
around freely in a demarcated space (Emmelkamp et al., 2002).
Concerning the exposure environments for the VR and in vivo
condition, some studies translated the in vivo environments
directly into VR environments (Emmelkamp et al., 2002;
Meyerbroeker et al., 2013), and others used in vivo environments
that slightly differed from the VR environments. In one study
on Social Phobia, in vivo group therapy was used to create a
real-life audience for participants delivering a speech (Anderson
et al., 2013). The study by Kampmann et al. (2016) provided
standardized social scenarios in the VR condition but conducted
exposure exercises on the participants’ individual social situations
in the in vivo condition. All included studies on Social Phobia
furthermore mention the realization of social interactions with
negative reactions of counterpart(s) in particular for the VR
condition but not for the in vivo condition. Anderson et al.
(2013) list bored, hostile and distracted as reactions of a virtual
audience, Kampmann et al. (2016) mention dialogues with an
unfriendly content, and - most pronounced - Bouchard et al.
(2016) name acting under the scrutiny of strangers and facing
criticism or insistence while meeting unfriendly neighbors or
while refusing to buy from a persistent shop seller as virtual
scenarios (see Table 2). In the two studies on fear of flying,
VR and in vivo exposure differed in that way that no real
flight was realized in the in vivo condition, but instead imaginal
exposure of take-off, flight and a landing was conducted while
sitting on a stationary plane (Rothbaum et al., 2000, 2006). In
the study on spider phobia (Michaliszyn et al., 2010), in vivo
exposure consisted of handling a living spider with the hands,
while no tactile feedback was provided in VR. As additional
interventions accompanying exposure, all studies conducted
introduction interventions like psychoeducation. Most studies
furthermore conducted cognitive or behavioral fear management
strategies in addition to pure exposure treatment (Rothbaum
et al., 2000, 2006; Botella et al., 2007; Michaliszyn et al., 2010;
Meyerbroeker et al., 2013; Anderson et al., 2016; Bouchard
et al., 2016). The two studies on Agoraphobia (Botella et al.,
2007; Meyerbroeker et al., 2013) and the two studies on flight
phobia (Rothbaum et al., 2000, 2006) applied interoceptive
exposure in addition to VR and in vivo exposure. In all studies,
additional interventions were conducted in the VR and the
in vivo condition.
Risk of Bias Within the Studies
To reduce the risk of bias within the included studies, only
randomized-controlled trials and only studies on participants
with valid diagnoses were selected. The main goal of this meta-
analyses was to compare studies that applied an equal amount
of exposure in the VR and in vivo condition, which is an
important contribution to reduce the risk of bias. However, it
should be noted that all studies were published by authors that
are researchers in the field of VR exposure, which may enhance a
particular risk of bias.
To assess common sources of bias within randomized-
controlled trials in detail, we used a bias detection tool from the
Cochrane Collaboration (Higgins et al., 2011). Altogether, our
assessment largely showed a low to unclear risk of bias in the
included studies (see Table 3). Concerning the risk of selection
bias in particular, all studies used random assignment, but not
all studies described the concrete procedure of random sequence
generation and allocation concealment. Concretely, there was an
unclear risk of selection bias in six studies, as the method of
random sequence generation and allocation concealment was not
further specified. One study reported an assignment based on a
computerized random number generator and the participation
of a third study coordinator to ensure an unknown allocation
before the participants’ enrollment (Anderson et al., 2013), one
study reported an assignment based on random number tables
and a concealed assignment not further specified (Bouchard et al.,
2016), and one study reported the use of a computerized random
number generator and a concealed assignment using envelopes
prepared by a third person and opened after enrollment of
the participants (Kampmann et al., 2016). All of the above
had a low selection bias risk. A performance bias must be
suspected in all studies, as the blinding of participants and
researchers during VR or, respectively, in vivo exposure was
not possible due to the nature of the intervention. Generally,
not all sources of bias can be avoided, due to the nature of
the applied intervention. A certain performance bias therefore
must be tolerated. Nevertheless, at least one study reported the
blinding of the participant and researcher until the exposure
component was applied, thereby enabling blind pre-processing
interventions (Botella et al., 2007). This procedure was rated
as low performance bias risk, considering the nature of the
treatment. Other studies did not further specify the time point
of de-blinding and therefore the risk of performance bias
concerning pre-processing remained unclear. Also blinding of
outcome assessment was not entirely realizable as the meta-
analysis was conducted on self-report measurements of phobic
fear and participants could therefore not be blind to the applied
condition at post measurement. Though, two studies realized
blinding during pre-assessment as an approximation (Botella
et al., 2007; Kampmann et al., 2016), both rated as low detection
bias risk under the decribed circumstances. Other studies did not
further specify if pre-processing was performed blind and were
rated as an unclear risk of detection bias. Risk of attrition bias
was low in many studies; however, some studies did not provide
sufficient information, therefore, risk of attrition bias remained
unclear. In studies with an intent-to-treat data, attrition bias was
rated as low, if losses to post-test were disclosed with respective
reasons, intent-to-treat analysis method was described, and if
means and standard deviations were reported with information
on the sample size in both groups (Meyerbroeker et al., 2013;
Bouchard et al., 2016). If those descriptions were incomplete
in studies with an intent-to-treat sample, attrition bias risk was
rated as unclear. One study, where the completers and intent-
to-treat sample were the same and outcome data therefore was
complete (Botella et al., 2007), was rated as having a low risk
of attrition bias. In studies with data for the completer sample,
risk of attrition bias was rated as low if a precise description of
attrition and exclusion of patients was provided (Rothbaum et al.,
2000; Emmelkamp et al., 2002). In comparison, in studies with
participants switching between conditions at an unspecified point
of time (Michaliszyn et al., 2010), risk of attrition bias was rated
as high. Risk of reporting bias was rated as low in all studies, as
prespecified outcome measures were all reported.
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TABLE 3 | Assessment of risk of bias within the studies.
Risk of selection bias Risk of performance
bias
Risk of detection
bias
Risk of
attrition bias
Risk of
reporting bias
References Random sequence
generation
Allocation
concealment
Blinding of participants
and researchers
Blinding of outcome
assessment
Incomplete
outcomedata
Selective
reporting
Rothbaum et al.,
2000
Unclear Unclear Unclear Unclear Low Low
Emmelkamp
et al., 2002
Unclear Unclear Unclear Unclear Low Low
Rothbaum et al.,
2006
Unclear Unclear Unclear Unclear Unclear Low
Michaliszyn
et al., 2010
Unclear Unclear Unclear Unclear High Low
Anderson et al.,
2013
Low Low Unclear Unclear Unclear Low
Kampmann
et al., 2016
Low Low Unclear Low Unclear Low
Bouchard et al.,
2016
Low Low Unclear Unclear Low Low
Botella et al.,
2007
Unclear Unclear Low Low Low Low
Meyerbroeker
et al., 2013
Unclear Unclear Unclear Unclear Low Low
Risk of bias was assessed using a tool from the Cochrane Collaboration (Higgins et al., 2011). Risk of bias was rated as low, unclear, or high.
Results of Individual Studies
Table 4 shows means and standard deviations of the anxiety
measures at pre and post assessment, as well as sepereate Hedges’
g effect sizes for pre-post treatment effects for both the VR
and in vivo group. Effect sizes for the VR exposure condition
ranged from 0.35 (Rothbaum et al., 2006) to 2.76 (Michaliszyn
et al., 2010), while effect sizes for the in vivo exposure condition
ranged from 0.31 (Rothbaum et al., 2006) to 3.86 (Michaliszyn
et al., 2010). Six studies conducted an intent-to-treat analysis
(Rothbaum et al., 2006; Botella et al., 2007; Anderson et al., 2013;
Meyerbroeker et al., 2013; Bouchard et al., 2016; Kampmann
et al., 2016), one of them reporting the same sample size
for participants included in the study and completers (Botella
et al., 2007). Three studies reported on the completer sample
(Rothbaum et al., 2000; Emmelkamp et al., 2002; Michaliszyn
et al., 2010).
In the comparison of the treatment effects of the VR exposure
and the in vivo exposure condition in the individual studies (see
Figure 2), one study showed a large (g ≥ 0.80) (Anderson et al.,
2013), two studies a medium (0.80 > g ≥ 0.50) (Rothbaum
et al., 2000; Kampmann et al., 2016) and one study a small
(0.50 > g ≥ 0.20) (Michaliszyn et al., 2010) negative effect size,
indicating superiority of in vivo exposure. One study showed a
small (0.50 > g ≥ 0.20) (Emmelkamp et al., 2002) and one study
a medium (0.80> g ≥ 0.50) (Bouchard et al., 2016) positive effect
size in the direction of superiority of VR exposure over in vivo
exposure therapy. Three studies showed an effect size around
zero (−0.06 to 0.02) and thereby below a small effect (g < 0.20)
(Rothbaum et al., 2006; Botella et al., 2007; Meyerbroeker et al.,
2013), pointing to no relevant difference between VR and in vivo
exposure therapy.
Synthesized Findings
Both, Virtual Reality exposure therapy (g = 1.00) and in vivo
exposure therapy (g = 1.07) showed a large, significant overall
effect size, when synthesizing the nine included studies (n =
371) on phobic anxiety disorders using a random-effect model
(see Table 5). Calculated separately for each phobic anxiety
disorder using fixed-effect models, VR exposure therapy showed
a medium, significant effect size in Specific Phobia (g = 0.68),
and a large, significant effect size in Social Phobia (g = 1.17) and
Agoraphobia (g = 0.99). in vivo exposure therapy also yielded
a medium, significant effect size in Specific Phobia (g = 0.72),
and a large, significant effect size in Social Phobia (g = 1.19) and
Agoraphobia (g = 0.90) (see Table 5).
For the comparison of the treatment effect of VR exposure
therapy and in vivo exposure therapy in all nine included studies
on phobic anxiety disorders (n= 371), using aHedges’ g random-
effects model, we obtained a mean overall effect size estimate of
Hedges’ g = −0.20, SE = 0.18, p = 0.271, 95% CI [−0.55, 0.16]
(see Figure 2). The negative effect size represents a difference of
mean treatment changes in the direction of superiority of in vivo
exposure, but the effect size was at the lower limit of a small effect
(0.50 > g ≥ 0.20) and therefore very small, and not significantly
different from zero. Accordingly, we found no evidence for a
significant difference in the efficacy of VR and in vivo exposure
therapy over all studies on phobic anxiety disorders.
To separately compare the treatment effects of VR exposure
and in vivo exposure therapy for the three subtypes of phobic
anxiety disorders, we applied fixed-effect models (see results
in Figure 2), which are appropriate for the small number of
studies included on each phobia. The pooled effect size for four
studies on Specific Phobia (n = 153) showed a non-significant
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TABLE 4 | Effect sizes for the pre-post treatment effects of VR exposure therapy and in vivo exposure therapy.
Pre Post Effect size
95% CI
References Phobia Sample Anxiety measure n M SD M SD g LL UL
Rothbaum et al., 2000 Specific Phobia Completer FFI VRET 15 105.85 35.91 86.14 37.40 0.51 −0.22 1.23
(fear of flying) IVET 15 133.30 42.00 87.53 42.30 1.03 0.17 1.88
Emmelkamp et al., 2002 Specific Phobia Completer AQ-Anxiety VRET 17 57.12 12.18 36.12 20.56 1.18 0.33 2.04
(fear of heights) IVET 16 59.06 17.12 42.19 17.14 0.93 0.13 1.74
Rothbaum et al., 2006 Specific Phobia ITT FFI VRET 29 120.38 44.24 103.69 49.35 0.35 −0.17 0.86
(fear of flying) IVET 29 116.79 57.74 100.34 43.49 0.31 −0.20 0.83
Michaliszyn et al., 2010 Specific Phobia
(fear of spiders)
Completera,b FSQ VRET 16 104.61 9.59 54.37 22.46 2.76 1.26 4.27
IVET 16 103.28 13.13 47.88 14.07 3.86 1.86 5.87
Anderson et al., 2013 Social Phobia ITT PRCS VRET 30 24.37 2.54 16.23 7.61 1.40 0.70 2.10
IVET 39 25.59 2.59 14.79 8.53 1.68 1.00 2.36
Kampmann et al., 2016 Social Phobia ITTa LSAS-SR VRET 20 73.00 17.25 55.74 18.65 0.92 0.20 1.64
IVET 20 69.15 19.44 39.22 25.01 1.28 0.46 2.10
Bouchard et al., 2016 Social Phobia ITT LSAS-SR VRET 17 85.1 29.5 51.8 23.3 1.19 0.34 2.05
IVET 22 74.9 24.5 56.0 26.9 0.71 0.07 1.35
Botella et al., 2007 Agoraphobia Completer= ITTc FQ-Agoraphobia VRET 12 16.27 14.19 6.82 7.61 0.77 −0.09 1.64
IVET 12 14.58 11.80 4.25 6.35 1.01 0.07 1.95
Meyerbroeker et al., 2013 Agoraphobia ITTb ACQ VRET 24 2.58 0.52 1.96 0.53 1.14 0.43 1.85
IVET 22 2.63 0.66 2.02 0.74 0.84 0.17 1.51
This table provides means and standard deviations of pre and post measurements on the stated anxiety measures, as well as pre to post effect sizes for VR exposure therapy (VRET) and
in vivo exposure therapy (IVET) of all studies included in the meta-analysis. Effect sizes were reported as Hedges’ g. The statistical values either refer to the completer sample (Completer)
or to the intent-to-treat sample (ITT), as mentioned. Studies are sorted by the type of phobia and date of publication. AQ-Anxiety, Acrophobia Questionnaire, Anxiety-subscale; FSQ,
Fear of Spiders Questionnaire; FFI, Fear of Flying Inventory; PRCS, Personal Report of Confidence as a Speaker; LSAS-SR, Liebowitz Social Anxiety Scale; FQ-Agoraphobia, Fear
Questionnaire – Agoraphobia; ACQ, Agoraphobic Cognition Questionnaire; CI, confidence interval; LL, lower limit; UL, upper limit.
aThe report did not present sample sizes and/or a declaration of ITT or completer sample in the table on means and standard deviations, information from the text was used
for specification.
bPatients from waitlists were allocated to the VRET and IVET condition and included in the analysis.
cThe authors reported the same sample size for the number of participants included in the study and the analysis sample.
result in favor of in vivo exposure that was below the level of
a small effect (g < 0.20), g = −0.15, SE = 0.16, p = 0.333,
95% CI [−0.47, 0.16]. This means that we found no significant
difference in the efficacy of VR exposure and in vivo exposure in
Specific Phobia. The pooled effect size of three studies on Social
Phobia (n = 148) showed a medium and significant effect size
favoring in vivo exposure, g = −0.50, SE = 0.17, p = 0.003,
95% CI [−0.83, −0.16]. Accordingly, VR exposure therapy was
found to be significantly less efficacious than in vivo exposure
therapy in Social Phobia. The pooled effect size for two studies
on Agoraphobia (n = 70) yielded a non-significant result close
to zero, g = −0.01, SE = 0.23, p = 0.959, 95% CI [−0.47,
0.45], not favoring one of the treatment conditions. This indicates
similar treatment effects of VR and in vivo exposure therapy
in Agoraphobia.
Risk of Bias
Visual inspection of a funnel plot (see Figure 3) showed a
sample of studies with relatively homogenous standard errors
and widespread effect sizes. There was no asymmetry detected
indicating a (publication) bias.
DISCUSSION
Summary and Discussion of Main Findings
Applying strict inclusion criteria to focus exclusively on the
comparison of VR and in vivo exposure, this meta-analysis
synthesized nine randomized-controlled trials with altogether
371 participants, comparing the pre to post treatment effects of
VR and in vivo exposure therapy in phobic anxiety disorders
applied with an equivalent amount of exposure and with
equivalent additional interventions alongside exposure in both
conditions. VR and in vivo exposure both yielded large effect sizes
concerning the reduction of phobic fear. For the comparison of
VR and in vivo exposure therapy, we found a small, but non-
significant effect size (g = −0.20, p = 0.271) favoring in vivo
exposure over VR exposure (see Figure 2). Although a non-
significant effect is not a final proof of equivalence, it shows
that there is no evidence that VR exposure is significantly less
efficacious than in vivo exposure therapy in phobic anxiety
disorders. The 95% confidence interval of the synthesized effect
size ranged from −0.55 to 0.16. This illustrates that the true
effect may lie in this range and that VR exposure could be
inferior to slightly superior in comparison to in vivo exposure.
Regarding previous meta-analyses on the comparison of VR
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FIGURE 2 | Forest plot with pre to post effect sizes for the comparison of VR exposure therapy to in vivo exposure therapy. All effect sizes are reported as Hedges’ g,
using a fixed-effect model or a random-effect model as stated. Negative effect sizes indicate superiority of in vivo exposure therapy, while positive effect sizes indicate
superiority of virtual reality exposure therapy. Studies are sorted by the type of phobia and date of publication.
TABLE 5 | Pooled effect sizes for the pre-post-treatment effects of VR exposure therapy and in vivo exposure therapy.
VR exposure In vivo exposure
95%CI 95% CI
Synthesis (Model; number of pooled studies) n g SEg p LL UL g SEg p LL UL
Specific Phobia (Fixed-Effect; n = 4) 153 0.68 0.22 <0.001 0.32 1.05 0.72 0.19 <0.001 0.34 1.10
Social Phobia (Fixed-Effect; n = 3) 148 1.17 0.22 <0.001 0.74 1.61 1.19 0.21 <0.001 0.79 1.60
Agoraphobia (Fixed-Effect; n = 2) 70 0.99 0.28 <0.001 0.44 1.54 0.90 0.28 0.001 0.35 1.44
All Phobic Anxiety Disorders (Random-Effect; n = 9) 371 1.00 0.18 <0.001 0.65 1.35 1.07 0.21 <0.001 0.66 1.47
This table presents pre to post effect sizes for VR exposure therapy and for in vivo exposure therapy pooled from studies on Specific Phobia, Social Phobia, Agoraphobia, and all studies.
Pooled effect sizes are reported as Hedges’ g using a fixed-effect model or random-effect model as stated. CI, confidence interval; LL, lower limit; UL, upper limit.
to in vivo exposure, a non-significant effect size is consistent
with the finding of a recent meta-analysis on VR versus in vivo
exposure in anxiety disorders by Carl et al. (2019), which showed
a non-significant, negative effect size in favor of in vivo exposure
(g = −0.07, p = 0.544). However, this effect size was even below
the level of a small effect. An earlier meta-analysis by Powers
and Emmelkamp (2008) even reported a small, positive effect
size in favor of VR exposure over in vivo exposure therapy (g =
0.34). Those differences of our results to former meta-analyses
comparing VR to in vivo exposure might be due to factors like
the number and type of studies included, the selected outcome
measures, or the data analysis strategy. Powers and Emmelkamp
(2008) included only five studies published until 2007 and in
this regard conducted their meta-analysis on a smaller sample
of original studies. Carl et al. (2019) synthesized 14 studies, and
included studies with a different amount of exposure between
conditions (Pelissolo et al., 2012), with imaginal instead of in vivo
exposure in the control group (Wallach et al., 2009), with in vivo
exposure only for patients with comorbid conditions in the
control group (Krijn et al., 2007), with VR presentation without
using immersive systems (e.g., HMD) and head tracking (Klinger
et al., 2005), as well as preliminary data (Robillard et al., 2010)
on an already included study (Bouchard et al., 2016). These
studies were excluded in our meta-analysis due to the stricter
inclusion criteria. As one important point, we ensured that in vivo
exposure was applied for all clients in the control condition
Frontiers in Psychology | www.frontiersin.org 16 September 2019 | Volume 10 | Article 1758
Wechsler et al. Virtual Reality Exposure in Phobias
FIGURE 3 | Funnel Plot for the detection of publication bias across studies with Hedges’ g on the x-axis and standard errors for Hedges’ g on the y-axis.
and in an equivalent amount to VR exposure. That might have
made the control condition more powerful thereby shifting our
overall effect size toward the superiority of in vivo exposure
in comparison to the previous meta-analysis. Furthermore, we
diminished potential sources of bias like dependent samples.
For example, the study consisting of preliminary data showed a
medium positive effect size in favor of VR exposure, whereby the
inclusion of this study in the meta-analysis by Carl et al. (2019)
might have moved their overall effect size toward VR exposure.
Considering the results for the individual studies included in
our meta-analysis, the effect sizes for the pre to post treatment
efficacy of VR in comparison to in vivo exposure therapy varied
largely (−1.02 to 0.53) (see Figure 2), with some favoring VR
exposure, some favoring in vivo exposure and some detecting no
relevant differences. The wide range shows the high potential of
VR, but also illustrates that VR exposure therapy could be less
efficacious than in vivo exposure therapy. This raises a discussion
on potential working mechanisms of a more or less efficacious
VR exposure therapy if compared to in vivo exposure. On the one
hand, variance in the effect sizes of the individual studiesmight be
due to confounding variables, like differences in the distribution
of participants’ characteristics for the two conditions (e.g., age,
comorbidities, or severity of phobic anxiety). On the other
hand, the variance could result from differences in the specific
materials and procedures of exposure therapy in the individual
studies (e.g., technical features of VR devices, realization of
VR and in vivo environments, or combination of exposure
with accompanying treatment elements, for example cognitive
interventions). Furthermore, it could be due to differences in
the efficacy of VR exposure for different kinds of phobic anxiety
disorders. We discuss these factors in the paragraphs that follow.
Looking separately at studies on Specific Phobia (n = 4),
we found a negative effect size in favor of in vivo exposure (g
= −0.15) (see Figure 2), which was however non-significant
and furthermore below the level of a small effect. VR exposure
consequently does not seem to be significantly less efficacious
than in vivo exposure in this phobic anxiety disorder. This is
consistent with the results of the latest meta-analysis on VR
versus in vivo exposure in anxiety disorders by Carl et al.
(2019), who particularly synthesized five studies comparing VR
and in vivo exposure in Specific Phobia. Other than Carl et al.
(2019), the meta-analysis conducted here, excluded a study with
in vivo exposure only for patients with comorbid conditions
in the control group (Krijn et al., 2007), and thereby could
prove the result for a sample of studies free from understated
in vivo conditions.
Behind the synthesized effect size of four studies on Specific
Phobia, the effect sizes of the individual studies ranged from
−0.65 to 0.27 (see Figure 2). It is important to mention that we
pooled studies on three different Specific Phobias (fear of heights,
fear of spiders and fear of flying) as there were not enough
articles published to synthesize results separately for each Specific
Phobia. Effect sizes indicating superiority of in vivo exposure
were found for two studies, one on fear of spiders (Michaliszyn
et al., 2010) and one on fear of flying (Rothbaum et al., 2000).
Michaliszyn et al. (2010) assumed that inferiority of VR exposure
might be based on an insufficient presence or problems with
cybersickness. Another aspect to consider is that in vivo exposure
was defined as successful in this study once patients could handle
a living spider in their hand (Michaliszyn et al., 2010). In contrast,
VR exposure did not consist of tactile stimulation (see Table 2)
which could have diminished its efficacy when compared to
in vivo exposure. Another point to explain inferiority of VR in
one study conducted earlier in time (Rothbaum et al., 2000)
might be the use of an older HMD technology. Against this
hypothesis speaks a comparison between the two studies on fear
of flying conducted by the group around Barabara Rothbaum
(Rothbaum et al., 2000, 2006) with a relative similar treatment
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proecedure. The study conducted 2006 pointed more toward
equivalency of VR and in vivo exposure than the earlier study
conducted 2000, although an HMD with an equal amount of
pixel and a lower field of view was used in the 2006 study (see
Table 2). Therefore, further potential (confounding) variables,
for example differences in the sample characteristics between
both studies, must be considered as relevant for the difference
in effect sizes. Another discussion point concerning those two
studies is, that Rothbaum et al. (2000) and Rothbaum et al.
(2006) both conducted an in vivo exposure of a parked plane but
only imaginal exposure of a takeoff, flying, and landing in the
control group. In contrast, VR exposure consisted of a takeoff,
landing, and flying in calm and stormy weather (see Table 2).
Therefore, a flight exposure conducted entirely in vivomight still
yield superior effects in comparison to VR exposure. Hence, the
comparison of VR and in vivo flight exposure is an interesting
question for future research. The study on fear of heights by
Emmelkamp et al. (2002), showing a small effect size favoring VR
therapy, indicates that VR exposure can be equally efficacious or
even superior than in vivo exposure. In this study, participants in
the VR group were exposed to exactly the same three situations
as participants in the in vivo group, which were rebuilt as
VR environments (see Table 2). Furthermore, participants could
walk around freely in a demarcated space during VR exposure in
this study, while other studies like for example Michaliszyn et al.
(2010) used a mouse for movements in VR (see Table 2). This
could potentially represent an advantage of the VR condition in
this study when compared to the VR conditions of other studies.
The result for studies on Agoraphobia (n= 2) distinctly points
to a similar efficacy of VR and in vivo exposure, as the synthesized
effect size is close to zero and non-significant (g = −0.01) (see
Figure 2). Here, the separate effect sizes for the individual studies
were homogeneous, ranging from−0.07 to 0.02. In both included
studies, participants were gradually exposed to situations like a
subway, public buildings, or supermarkets in VR, and a similar
in vivo exposure was applied in the control group (Botella et al.,
2007; Meyerbroeker et al., 2013) (see Table 2). Unlike our result,
the meta-analysis on VR versus in vivo exposure in anxiety
disorders by Carl et al. (2019) synthesized three studies on Panic
Disorder with Agoraphobia and found a small, negative effect size
in favor of in vivo exposure (g = −0.26), which was, however,
non-significant. Carl et al. (2019) additionally included one study
that performed CBT methods classically recommended for panic
disorder (among them in vivo exposure) in the control group, and
VR exposure to different environments as the main intervention
in the experimental group (Pelissolo et al., 2012). This study
yielded a negative effect size in favouring of in vivo exposure,
which might possibly be due to the application of interventions
relevant for panic disorder patients such as relaxation training,
cognitive interventions, and interoceptive exposure in the in
vivo but not in the VR condition. The study was excluded
from our meta-analysis due to the stricter eligibility criteria
of an equivalent amount of exposure and the equivalency of
additional interventions in the VR and in vivo condition. Its
negative effect size probably explains the stronger trend in
favor of in vivo exposure for Agoraphobia in the meta-analysis
by Carl et al. (2019). The two studies included in our meta-
analysis on Agoraphobia conducted cognitive interventions and
interoceptive exposure as additional interventions in both the VR
and in vivo exposure group (Botella et al., 2007; Meyerbroeker
et al., 2013) (see Table 2). Considering this, we suspect that VR
and in vivo exposure in Agoraphobia show a similar efficacy
in studies with a highly comparable treatment procedure of
exposure and additional interventions in VR and in vivo therapy.
Interestingly, we found a significant, medium effect size (g =
−0.50) in favor of in vivo exposure in the synthesis of studies
comparing VR and in vivo exposure in Social Phobia (n = 3)
(see Figure 2). This indicates evidence for the superiority of
in vivo exposure in Social Phobia and therefore represents an
inconsistency to former meta-analyses. So, Chesham et al. (2018)
found an extremely small, non-significant effect in favor of VR
exposure when pooling five randomized trials comparing VR
exposure with standard treatment (in vivo or imaginal exposure)
for Social Anxiety. Also, Carl et al. (2019) found a small, non-
significant effect in favor of VR exposure when comparing to
in vivo exposure in six studies on Social Anxiety and Performance
Anxiety. Unlike Carl et al. (2019) and Chesham et al. (2018),
we excluded studies with imaginal exposure or with a video-
taped visualization procedure but with no in vivo exposure as the
control group (Wallach et al., 2009; Heuett and Heuett, 2011),
because the abscence of in vivo exposure could lower the efficacy
of the control condition in contrast to the VR condition. Both
studies actually yielded either a positive effect size in favor for VR
exposure (Heuett and Heuett, 2011) or an effect size close to zero,
while not favoring VR or in vivo exposure (Wallach et al., 2009).
Moreover, unlike Carl et al. (2019) we excluded studies with VR
presentation without using immersive systems (e.g., HMD) and
head tracking (Klinger et al., 2005), and studies on preliminary
data on already included trials (Robillard et al., 2010), that both
yielded positive effect sizes in favor of VR. The exclusion of
those four studies in our meta-analysis can probably explain why
our results differ from the meta-analysis by Carl et al. (2019) or
Chesham et al. (2018).
We found a superiority of in vivo exposure over VR exposure
only in Social Phobia but not in Agoraphobia and Specific Phobia,
indicating that it might be more difficult to create virtual social
environments for Social Phobia exposure than virtual spiders,
heights and airplanes for Specific Phobia exposure, or virtual
shopping malls, subways, or tunnels for Agoraphobia exposure.
In addition, Social Phobia is considered to be a more complex
disorder with high comorbidity, chronicity, and impairment
(Wittchen and Fehm, 2003), and shows lower remission rates
in CBT treatments than other anxiety disorders (Springer et al.,
2018). Actually, these issues should affect VR as well as in vivo
exposure therapy in Social Phobia. Nevertheless, it might be
easier to activate specific dysfunctional beliefs of Social Phobia
patients (e.g., concerning what others think of them) in vivo
than in VR. In general, the creation of avatars, agents, and social
interactions for VR settings is an issue which is challenging not
only for psychological but also for computer science research. As
an example, the degree of naturalism required for virtual agents is
being intensively discussed, which seems to not be linearly related
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to the users’ acceptance of the agent (“uncanny valley effect”) (see
for e.g., Stein and Ohler, 2017; Schwind et al., 2018).
The effect sizes on the comparison of VR to in vivo exposure
from the individual reports on Social Phobia ranged from −1.02
to 0.53 (see Figure 2). This shows that VR exposure was partially
inferior and partially superior to in vivo exposure in the studies
included in our meta-analysis. An effect size favoring in vivo
exposure was found in the study on public speaking phobia
by Anderson et al. (2013) in which participants were asked to
deliver a speech in front of a virtual audience varying in size,
if assigned to the VR condition, or respectively, in front of a
real audience in a group therapy setting if allocated to the in
vivo group (Anderson et al., 2013) (see Table 2). In VR, the
audience members could be manipulated on their reactions (e.g.,
bored or interested; see Table 2) and could pose standardized
questions (Anderson et al., 2013). As an important difference,
participants in the in vivo group not only delivered their own
speech but additionally listened to the speeches of other group
therapy members and received positive feedback on their own
videotaped speeches from the whole group instead of only from
the therapist like realized in the VR condition (Anderson et al.,
2013) (see Table 2). According to the authors of the study, the
group setting might have been of a stronger interpersonal nature
than the VR environment. Furthermore, they considered the
feedback as a higher dose of exposure in the in vivo condition
(Anderson et al., 2013). Above that, one might speculate that
the in vivo condition provided a higher individualization in
social interactions in contrast to the standardized reactions
and questions of the virtual audience in the VR condition.
Furthermore, positive feedback from numerous peers might have
supported cognitive reinterpretations of the feared situation and
observing speeches from other participants could have possibly
worked as model learning. This might represent advantages of
the in vivo in contrast to the VR condition. In the second study
yielding an effect size in favor of in vivo exposure (Kampmann
et al., 2016), a gradual exposure to different standardized social
situations with standardized dialogues with different content
and style from friendly to unfriendly and with varying personal
relevance was conducted in the VR group, whereas individual
social situations were translated to in vivo exposure exercises
in the in vivo control group, and also exposure in the personal
environment of the participants was realized in this condition
(see Table 2). Both conditions were not combined with cognitive
interventions to examine the pure effect of exposure therapy
(Kampmann et al., 2016). It might be possible that a stronger
individualization of the situations in the in vivo group resulted
in a higher efficacy of in vivo in comparison to VR exposure.
The authors of the study furthermore speculated that the results
could be attributed to the fact that it was their first version
of a Social Anxiety VR environment, and moreover mentioned
that VR exposure for Social Phobia might need to be combined
with cognitive elements to improve efficacy (Kampmann et al.,
2016). Superiority of VR exposure in Social Phobia was actually
achieved in a study which realized social situations in VR and in
vivo while focusing on cognitive restructuring without requiring
habituation (Bouchard et al., 2016) (see Table 2). The authors
of the study pointed out that cognitive interventions might
influence the way exposure is mentally processed by the patients.
As a further difference to the study conducted by Kampmann
et al. (2016), the therapist was present in the same room during
VR exposure. Bouchard et al. (2016) in this regard considered
a better therapeutic alliance in the VR condition as another
possible explanation for the different results. As a difference to
the studies conducted by Anderson et al. (2013) and Kampmann
et al. (2016), Bouchard et al. (2016) partially used role-playing
for exposure in the in vivo condition. One might argue that
role-play causes less fear activation than social situations in real-
life, which could have lowered the efficacy of the in vivo in
comparison to the VR condition of this study. Furthermore, it
is to mention that the social situations realized in the in vivo
condition of the study by Bouchard et al. (2016) seem to be
less individualized in comparison to the study conducted by
Kampmann et al. (2016). Finally, in the study by Bouchard
et al. (2016) VR exposure scenarios included social interactions
like acting under the scrutiny of strangers, being refused, or
facing criticism or insistence that were not described for the
in vivo condition (see Table 2). Although negative reactions of
virtual counterparts were also realized in the studies by Anderson
et al. (2013) and Kampmann et al. (2016) (see Table 2), they
seem more pronounced in the study by Bouchard et al. (2016).
Because negative reactions of a counterpart target central fears
of Social Phobic patients, this might - especially when combined
with cognitive interventions - for example facilitate expectancy
violation concerning catastrophic beliefs. This could be a further
aspect explaining why VR exposure was more efficacious than
in vivo exposure in this study. Overall, real humans’ reactions
cannot be manipulated in the same systematical way as in
VR, and social interactions comprising rejection are therefore
not easily realized in vivo. This might generally represent an
advantage of VR over in vivo exposure in Social Phobia.
To further discuss variables that might have influenced the
efficacy of VR in comparison to in vivo exposure therapy,
differences in the participants’ characteristics, in the technical
features of VR devices, and in the concrete kind of VR and in vivo
exposure environments and procedures are considered.
As one sample characteristic, we looked at differences in the
participants’ age in all included studies. Age ranged from 18
to 72 years, with a mean age over both experimental groups
ranging from 29.1 to 43.97 years (see Table 1). Although the
variance was not strikingly high, differences in the participants’
age between the individual studies might have had an influence
on the efficacy of the VR exposure treatment for example.
One might hypothesize that younger participants profit more
from a VR treatment than older participants, as they are more
familiar with this technique. Contradictory to this hypothesis,
VR exposure was inferior to in vivo exposure (g = −0.44) in
the study which included the youngest participants (age M =
29.1, SD = 7.99) (Michaliszyn et al., 2010). Furthermore, the
study which included the oldest participants (age M = 43.97,
SD = 9.34) showed a result in favor of VR exposure therapy
(g = 0.27) (Emmelkamp et al., 2002). And also over all studies,
visually inspection does not show a distinct positive relationship
between the efficacy of VR in comparison to in vivo exposure and
the mean age of the participants. Further sample characteristics
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like disorder severity, comorbidities, or medication for example,
could not systematically be examined, as they have not been
measured homogeneously in the different studies.
Another point to consider is the changes VR technologies
experienced from 2000 to 2016, during the period in which
the included studies were published. One might argue that the
technical development of VR devices could have affected the
therapy results in the VR exposure condition, while the in vivo
exposure procedure stayed relatively unchanged. In this regard,
better developed VR techniques might have led to higher efficacy
of VR exposure treatments in comparison to in vivo exposure. As
already mentioned in the discussion on effect sizes for Specific
Phobia, the results for the studies by Rothbaum et al. (2000,
2006) do not point to this hypothesis. For a deeper examination,
we provide a description of the resolution and field of view
of the different types of HMDs used in the individual studies
included in this meta-analysis (see Table 2). Over all studies,
visual inspection does not show a positive relationship between
the efficacy of VR in comparison to in vivo exposure and the
technical development of the HMD devices. For example, VR
exposure conducted with a nVisor SX, as a VR device with a - for
the first decade of the century- relatively high resolution and a
wide field of view (1280× 1024/60◦), in one case shows a similar
efficacy of VR to in vivo exposure (g = 0.02) (Meyerbroeker
et al., 2013), and an inferior efficacy of VR in another case
(g = −0.68) (Kampmann et al., 2016). Moreover, studies using
a VFX, as a type of HMD with a lower resolution and field of
view (640 × 480/35◦), also point at similarity between VR and
in vivo exposure (Rothbaum et al., 2006), or show inferiority of
VR exposure (Anderson et al., 2013). Studies conducted with a
V6, as another type of HMD (640 × 480/60◦), point at similarity
between VR and in vivo exposure (g = −0.07) (Botella et al.,
2007), or show an effect size in favor of in vivo exposure (g =
−0.65) (Rothbaum et al., 2000).
Finally, variables like age and technical development of
HMDs alone cannot explain differences in the efficacy of
VR in comparison to in vivo exposure therapy in all the
studies included in this meta-analysis. Instead, different modes
of movement in VR, individualization of VR scenarios, the
therapeutic alliance in VR exposure, the combination of VR
exposure with cognitive interventions, and the creation of
virtual social interactions targeting central fears are interesting
factors to be considered in future research on the effective
factors of VR exposure therapy, especially in Social Phobia. As
soon as more studies are available, systematic meta-regression
analysis could statistically examine the influence of certain
variables on the efficacy of VR in comparison to in vivo
exposure therapy. Therefore, original studies should not only
control for participants’ characteristics characteristics such as
disorder severity, comorbidity, or accompanying medication as
potential confounding variables, but also systematically describe
their materials and procedure in matters of the VR settings
such as movement mode in VR, stimulation of further senses
alongside the sense of sight, design of virtual social interactions,
exposure strategy, role of the therapist during exposure, as
well as realization of theoretical and empirical approaches such
as cognitive restructuring and inhibitory learning. Moreover,
experimental studies could systematically variegate potential
effective factors thereby providing findings on a causal influence
on the efficacy of VR exposure. By doing this, future studies
could reveal more about efficacious application procedures of VR
exposure therapy.
Limitations
The main limitation of this meta-analysis is the relatively small
number of included studies, as only nine published articles
fulfilled the eligibility criteria. This limits the generalizability of
the results, especially for the specific phobic anxiety disorders.
On the other hand, a statistical summary, even of a small number
of studies, can be meaningful since it prevents intuitive ad
hoc summaries which are often highly misleading (Borenstein
et al., 2009). However, the relatively strict inclusion criteria of
this meta-analysis for the participants, procedures, materials,
and study design resulted in pooled effect sizes from a sample
of highly comparable studies with a study methodology that
was of comparatively good quality, but which could have been
improved on.
As one eligibility criterion, we only included studies of
participants diagnosed with an ICD or DSM phobic anxiety
disorder, resulting in a relatively homogeneous sample of all
studies. However, the inclusion of studies on three different
phobic anxiety disorders resulted in a certain variance between
participants. Moreover, there were studies which included
participants diagnosed with other (phobic) anxiety disorders
than the target disorder of the particular study. Those were, in
particular, patients with Agoraphobia in the two studies on fear
of flying (Rothbaum et al., 2000, 2006) and participants with
Panic Disorder without Agoraphobia in a study on Agoraphobia
(Botella et al., 2007) (see Table 1), which could cause a certain
bias if those participants were not equally distributed in the
experimental conditions.
Another limitation lies in the use of different anxiety
measurements across different studies, which could have biased
the synthesized effect sizes. As we calculated effect sizes on
symptom specific anxiety measurements, it was necessary to
pool different assessments for Specific Phobia, Social Phobia
and Agoraphobia, but also, studies on the same phobic anxiety
disorder applied different symptom specific measurement (see
Table 4). Moreover, we only included self-report measurements,
as there were not enough studies which conducted comparable
objective measures, like behavioral avoidance tasks. Though,
as standardized test were used, those should have generated
sufficiently reliable and valid measurements.
Regarding VR equipment, only studies using VR devices
with immersive systems (e.g., HMD) and head tracking were
included, leading to a relatively homogeneous application of VR
stimuli. Nevertheless, the studies did not all use the same type
of hardware, such as different types of HMDs (see Table 2) and
different types of software as a potential source of variance for
example. One study partly used an HMD and partly a CAVE
system as the VR presentationmode (seeTable 2), but in this case
no significant differences in the outcome measures were found
(Meyerbroeker et al., 2013).
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Concerning the treatment procedure, a similar amount of
exposure in the VR and in vivo condition was required according
to the eligibility criteria. Nevertheless, the exposure environment
in VR and in vivo was not always equal (see Table 2). For
example, two studies conducted a flight exposure in VR, but
only exposed participants to sitting on a stationary plane with
imaginal exposure of a flight in the in vivo condition (Rothbaum
et al., 2000, 2006). Moreover, over different studies there were
differences in the amount and kind of therapeutic techniques
applied for pre- and post-proceeding and to accompany exposure
treatment (see Table 2). For example, Social Phobia exposure was
combined with cognitive techniques in the study by Bouchard
et al. (2016), but not in the study by Kampmann et al. (2016).
A limitation of the included data is that the original studies
differed in providing either data on an intent-to-treat sample,
a completer sample, or both. If available, intent-to-treat data
was used for synthesis, but if not provided, data on completer
samples was included (see Table 4). This should be considered
as a potential source of bias. Future original studies should thus
provide data on both samples, so that separate meta-analysis can
be conducted.
A limitation concerning the synthesis of data is the use of
fixed-effect models for pooling a smaller number of studies
on one specific kind of phobic anxiety disorder. A fixed-
effect model requires functionally identical studies (Borenstein
et al., 2009), which can approximately be reached by the strict
inclusion criteria and focusing on only one phobic disorder for
the synthesis. Nevertheless, the included studies on one phobic
anxiety disorder were not entirely identical and therefore the
results must be interpreted cautiously and should not be used for
generalizations on a wider population (Borenstein et al., 2009).
They do however provide a descriptive analysis of differences
concerning the treatment effects of VR and in vivo exposure
therapy in different phobias and allow a discussion on potential
mechanisms behind differences in effect sizes for the comparison
of VR and in vivo exposure therapy between different phobic
anxiety disorder.
Furthermore, the applied statistical tests are only valid
for testing differences between groups, but not for proving
equivalency. Therefore, the non-significant results have to be
interpreted cautiously and the relevance of effect sizes has to be
considered. Future meta-analyses based on a larger number of
trials should also draw on non-inferiority or equivalence tests
(Piaggio et al., 2006) to examine the equivalence of VR and in
vivo exposure.
Finally, we could not conduct a statistical analysis of potential
effective factors of VR exposure therapy due to the small number
of available studies. As soon as more original studies have been
published, this will also be an important research question for
future meta-analyses.
In general, this meta-analysis and the original studies
were conducted by researchers in the field of VR. This is a
potential source of bias, especially as no pre-registration of this
systematic review and meta-analysis protocol was conducted.
However, we comprehensively disclose our methods and results.
Furthermore, as there are no original studies available from
field-independent researchers, we provide a comprehensive and
objective description of the materials and procedures of all
studies included in this meta-analysis. In this regard, we want
to enable the reader to capture information for an independent
assessment and interpretation of the results and thereby attenuate
the bias caused by non-independent researchers.
Conclusions
Thismeta-analysis provides results on a head to head comparison
of VR exposure and in vivo exposure as the golden standard
of treatment for phobias, synthesized from methodologically
comparable studies with an equivalent amount of exposure in VR
and in vivo, and with equivalent interventions applied alongside
VR and in vivo exposure in phobic anxiety disorders, especially
in Agoraphobia and Specific Phobia. For Social Phobia, the
synthesized effect size points to a superiority of in vivo exposure,
but the wide range of effect sizes for the individual studies
also shows the high potential of VR exposure in this phobic
anxiety disorder.
While the individual effect sizes for the studies on
Agoraphobia both indicate equivalency between VR and
in vivo exposure, the individual effect sizes for the studies on
Specific Phobia and Social Phobia ranged from inferiority to
equivalency and even superiority of VR exposure. Studies that
yielded an equivalent or even superior effect of VR exposure
combined an exposure of agoraphobic situations in VR and
in vivo with cognitive interventions and interoceptive exposure
(Botella et al., 2007; Meyerbroeker et al., 2013), realized an
equivalent environment for the exposure of fear of heights in
VR as in vivo and allowed patients to move in VR by walking
around freely in a demarcated space (Emmelkamp et al., 2002),
or focused on reinterpretations without requiring habituation
during VR and in vivo exposure in Social Phobia and applied
social interactions realizing rejection experiences in the VR
condition (Bouchard et al., 2016). Although a statistical analysis
of potential effective factors was not possible, such observations
can contribute to the implementation of maximized efficacious
VR exposure therapy. There are hints that VR exposure in Social
Phobia should be combined with cognitive interventions and
should use the possibility to manipulate virtual agents in order
to target central fears of Social Phobic patients to reach equal or
even better efficacy in comparison to in vivo exposure.
Considering the results of this meta-analysis, and because
there are barriers in conducting in vivo exposure in clinical
practice (Neudeck and Einsle, 2012), it would be strategically
useful to promote the dissemination of VR comprehensively.
As VR therapy is time-effective, accounts for less organizational
effort (Diemer et al., 2015), and has a higher acceptance in
patients (García-Palacios et al., 2007), this could be a feasible
possibility in achieving efficacious exposure treatment for a wider
population of patients.
As there were only a few studies with sufficiently homogenous
materials and procedures published on the examined research
question, this meta-analysis is still based on a small number
of studies. A proportionally high level of internal validity can
be expected for the results, but the generalizability should
be verified in an updated meta-analysis as soon as more
studies are published in the following years. In addition,
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future research should focus on the effective factors of VR
exposure therapy and further examine mechanisms enhancing
the treatment effects that may be applicable using VR exposure.
Examples are the impact of cognitive strategies (see the study
conducted by Bouchard et al., 2016), the movement mode in
VR (mouse/gamepad vs. walking freely in a demarcated space
as achieved in the study conducted by Emmelkamp et al., 2002),
or the repetition of exposure with different stimuli or contexts
(Shiban et al., 2013, 2015). Further interesting research questions
include multimodal exposure (Peperkorn et al., 2016), eligible
patient population, or a different amount of VR sessions applied.
As VR materials and procedures continuously improve, superior
effects of VR exposure in comparison to in vivo exposure therapy
could be realized in future. This is because VR has the possibility
to create ideal environments for exposure, for example virtual
rejection experiences targeting central fears of Social Phobia
patients as for example achieved in the study conducted by
Bouchard et al. (2016), and also has the possibility to consider
and test theoretical and practical concepts, for example inhibitory
learning and inhibitory regulation (Craske et al., 2008; Craske,
2015). The creation of complex virtual social interactions is
therefore a challenge that can be solved in future research and
VR scenario development.
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